It’s been a fairly positive day for the S&P/ASX 200 Index (ASX: XJO) and ASX shares so far this Friday. At the time of writing, the ASX 200 is up 0.22% at 6,543 points. But it’s been an even better day for the Novonix Ltd (ASX: NVX) share price.

Novonix shares are presently enjoying a 10.7% bounce to $2.38 each. It was only yesterday that this ASX battery technology share was recording a new 52-week low of $2.07 a share. That price was more than 82% off the all-time high of $12.47 a share that we saw back in December last year.

But Novonix shares are seemingly putting all of that behind them today.

So what’s going on here?

Why are Novonix shares jumping on an 11% rocket?

Well, it’s nothing out from the company itself, given Novonix has not released any news or announcements since 14 June.

However, we are seeing a bit of a trend forming on the ASX boards today. ASX battery and lithium shares are on fire this Friday.

In addition to Novonix’s move, we have Pilbara Minerals Ltd (ASX: PLS) up 6.8%, Core Lithium Ltd (ASX: CXO) up 7.7%, and Liontown Resources Limited (ASX: LTR) rising 11.1%.

This comes after a bullish prediction regarding lithium was aired yesterday.

As we covered at the time, broker Macquarie has upgraded its forecast for lithium prices. It “now expects spodumene prices to peak at US$4,900 a tonne in the September quarter”. As a result, Macquarie “has upgraded its short-term and medium-term forecasts by 8% to 13% per tonne”.

So perhaps it is this bullish prediction that has investors all riled up over lithium and battery shares today. Or perhaps investors just decided that the share prices of Novonix and others we were seeing yesterday were too cheap, and have bought back in today.

Whatever the reason, it’s certainly been a pleasing day for Novonix shareholders thus far on Friday.

At the current Novonix share price, this ASX battery share has a market capitalisation of $1.17 billion.

The post Wow! Novonix share price rebounds off a 52-week low to surge 11% appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• Why is the Novonix share price plunging 6% on Wednesday?
• Why is the Novonix share price charging 7% higher today?
• These were the worst performing ASX 200 shares last week
• Novonix share price loses 20% in dire week for ASX 200 tech stocks
• The Novonix share price is the worst of the ASX 200 losers today. What’s going on?

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Macquarie Group Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/Rd19gnJ

The Lake Resources N.L. (ASX: LKE) share price is surging upwards on Friday amid the release of a market update.

The company has reassured the market that ambitions for its Argentinian projects remain the same following its pivot towards the North American market.

At the time of writing, the Lake Resources share price is 83 cents, 18.57% higher than its previous close.

Unfortunately, today’s gain hasn’t been enough to see the stock recovering this week’s tumble. It’s still trading 41% lower than it was at last Friday’s close.

For context, the broader market is also in the green today. The S&P/ASX 200 Index (ASX: XJO) is currently up 0.25% while the All Ordinaries Index (ASX: XAO) has gained 0.48%.

Let’s take a closer look at today’s release from the ASX 200 lithium explorer.

Lake Resources share price surges on Friday

The Lake Resources share price has suffered this week amid news of its planned transition towards North American and Asian lithium supply chains, its addition to the ASX 200, and a broader lithium sell-off.

The company announced North America managing director Steve Promnitz was stepping down after establishing Lake Resource’s dominant position in Argentina on Monday.

It also announced that its chair Stu Crow has been appointed executive chair for six months to oversee the establishment of the company’s North American presence. Crow will direct the appointment of a new CEO, board members, and the creation of US offices.

The company addressed potential concerns regarding the change in a non-price sensitive release today, saying:

Nothing has changed in respect of [Lake Resource’s] desire to progress development of the Kachi and other projects in Argentina to meet rising demand in the US and other western markets.

It also noted that Promnitz’ decision to step down was “of his own volition” and stated he didn’t provide a reason for his departure. Key negotiations and happenings will continue despite Promnitz’ departure.

Finally, the company told the market:

There is an urgency in the US to secure battery metal supply chains … Crow is currently in the US with a view to progressing the outlined strategy.

What’s going on with ASX lithium shares this week?

Prior to today, the Lake Resources share price had tumbled nearly 54% this week amid a broader lithium sell-off.

It was joined in the red by shares in its fellow ASX lithium favourites.

Those in Core Lithium Ltd (ASX: CXO), Liontown Resources Limited (ASX: LTR), and Sayona Mining Ltd (ASX: SYA) fell 27%, 14%, and 14% respectively between the end of last week and Thursday’s close. They’re all also in the green today.

As my Foolish colleague James reported, this week’s sell-off might have had something to with the news that Germany may refuse to ban fossil fuel-powered cars by 2035.

Lake Resources share price snapshot

Today’s gains included, the Lake Resources share price is nearly 24% lower than it was at the start of 2022. Though, it has gained 151% since this time last year.

The post ‘Nothing has changed’: Why the Lake Resources share price is rocketing 19% today appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• ASX 200 midday update: Qantas’ market update, lithium shares rebound
• Could ASX lithium shares be set for a boost?
• Here are the 3 most heavily traded ASX 200 shares on Thursday
• Why Cooper Energy, Lake Resources, Leo Lithium, and Zip shares are sinking
• The Lake Resources share price has crashed 50% since joining the ASX 200 on Monday. What’s going on?

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/YH2FqDb

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Netflix (NASDAQ: NFLX) stock has been experiencing a miserable run over the past six months. The streaming pioneer thrived in the early stages of the pandemic when folks were staying at home more often and demand for entertainment was surging. Meanwhile, the COVID-19 restrictions meant that the entire industry paused content creation, saving billions in cash for Netflix. 

Those ideal conditions have quickly vanished while headwinds are gaining momentum. Netflix went from adding millions of subscribers every quarter to now reporting losses. The stock is down 75% off its highs as a consequence. However, Netflix could be at a tipping point where investors may want to take notice.

Investors fear subscriber losses will continue 

In its most recent quarter, which ended on March 31, Netflix noted that it lost 200,000 subscribers from the quarter before. That was its first such quarterly decline in over 10 years. But what made matters worse was that Netflix forecast another loss in the second quarter of 10 times that magnitude. If it comes to fruition, the expected 2 million subscriber loss in Q2 will now make it a trend of subscriber losses rather than a one-off event. That is understandably spooking investors uncertain about how long or deep it will be.

A meaningful part of the stock’s decline is due to those fears. Therefore, if Netflix, in its next quarterly update, informs investors that it expects subscriber losses to subside and issues a forecast for millions of new customers in Q3, it could cause the stock to reverse higher. While the current quarter may not hold significant catalysts to boost subscriber growth, the next may be different. Inflation is biting into consumer budgets, forcing them to make the tough decisions on where to save money because they are paying more for necessities like food and gas. 

US Consumer Price Index YoY data by YCharts

At less than $20 per month, Netflix is arguably an affordable entertainment option for families worldwide. In contrast, a visit to the movie theater could cost five times as much for a family of four (including concessions). And a concert, theme park, or sporting event could be multiples higher than even that amount. Of course, there are cheaper streaming service options, but Netflix has announced its own lower-priced, ad-supported tier that could be available this year. 

Macroeconomic conditions have been a significant headwind for Netflix in 2022; those look like they are at their nadir. The turnaround might be a tipping point that could send Netflix’s stock higher. 

Netflix’s cheap valuation could propel it higher

NFLX PE Ratio data by YCharts

Netflix is trading at a price-to-earnings of 15.9, its lowest in the last five years. The cheap valuation suggests that once investors observe the turnaround in subscriber losses, the stock could jump in response. The longer-run trend is on Netflix’s side with consumers canceling traditional cable subscriptions and streaming their content instead.

The short-term headwinds are bound to subside; it appears a question of “when not if.” Rather than trying to time the bottom, investors may want to start adding a position in Netflix stock now.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

The post Is Netflix stock at a tipping point? appeared first on The Motley Fool Australia.

(function() { function setButtonColorDefaults(param, property, defaultValue) { if( !param || !param.includes(‘#’)) { var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0]; button.style[property] = defaultValue; } } setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’); setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’); setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’); })()

More reading

• Why is everyone talking about Netflix stock?
• Can Stranger Things stop Netflix’s subscriber bleed?

Parkev Tatevosian has positions in Netflix. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Netflix. The Motley Fool Australia has recommended Netflix. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

from The Motley Fool Australia https://ift.tt/O2IhzTn

ASX travel shares are back in the spotlight now that COVID-19 has stepped back into the shadows.

The industry got a vote of confidence today after Regional Express Holdings Ltd (ASX: REX) announced a 10-year agreement with Flight Centre Travel Group Ltd (ASX: FLT).

Additionally, Rex revealed it has also signed agreements with ASX travel shares Helloworld Travel Ltd (ASX: HLO), Webjet Limited (ASX: WEB), and Corporate Travel Management Ltd (ASX: CTD), plus Consolidated Travel.

ASX travel shares team up

Revealing its “multiple agreements with major travel agency groups”, Rex picked out one deal for special mention.

“In particular, Rex has signed a landmark 10-year agreement with Flight Centre which ensures that Rex will be Flight Centre’s partner of choice over the next decade,” it said.

Rex said all the agreements will be in effect at the start of the new financial year beginning July 2023.

The ASX travel share expects the deals to result in a “more than doubling of Rex’s annual domestic jet revenues in FY2023 compared to its current annualised domestic jet revenues with no increase in fleet size”.

It also expects its regional revenue to be improved.

Speaking on the announcement, Rex’s general manager of sales Ann Elliott said the new partnerships were “critical to success”.

“These new partnerships are a testament to our growing reputation as a safe, reliable and affordable full-service airline which is enjoying ever-increasing passenger support,” she added.

Share price snapshot

At the time of writing, the Rex share price is up 0.99% at $1.02. It is down almost 28% this year to date and 18% over the past year.

The Flight Centre share price is currently down 1.15% today at $17.24. It has fallen 7% since the start of the year but is up 15% over the past 12 months.

The post These 2 ASX travel shares are tying the knot for the next 10 years appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#43B02A”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43B02A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• Flight Centre share price stumbles amid ‘big blow’ from new tax
• ASX 200 travel shares take off again on Tuesday. Here’s why
• Why are ASX 200 travel shares lifting off on Monday?
• These are the 10 most shorted ASX shares
• Flight Centre share price climbs amid $30m investment in staff

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Helloworld Limited. The Motley Fool Australia has positions in and has recommended Helloworld Limited. The Motley Fool Australia has recommended Corporate Travel Management Limited, Flight Centre Travel Group Limited, and Webjet Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/rPDNeAg

It’s certainly been a tough time for the Challenger Ltd (ASX: CGF) share price of late. Challenger shares are today down a painful 1.05% at $6.57 a share. That’s in stark contrast to the S&P/ASX 200 Index (ASX: XJO), which is currently in the green, having recorded a 0.31% gain so far today.

But Challenger’s woes go further back than today. This annuities provider has now slid by a nasty 13.3% over the past month alone. It was only last month that we saw Challenger at a 52-week high of $7.72 a share.

The past month’s dreary performance comes despite there being a total lack of news or announcements out of the company. So does this mean we could be looking at a buying opportunity for Challenger shares here?

Is the Challenger share price a buy today after a 12% slide?

Well, one expert who thinks it might be is TMS Capital portfolio manager Ben Clark. Last month, we covered how Clark chose Challenger as his pick for a higher interest rate world. Here’s some of what he said:

[Challenger is] effectively Salesforce Inc (NYSE: CRM), with financial planners pushing their products, particularly bank-employed financial planners. But it was also impacted by the move in cash rates to zero. Annuities don’t sound particularly attractive when you’re locking in a 1% rate for the rest of your life…

[It’s now] much more closely aligned to institutional solutions for annuities, particularly things like inflation linked to annuities and more boutique solutions to problems in big LICs… there’s earnings momentum coming back.

But Clark is not the only one bullish on Challenger. Last month, we also covered ASX broker UBS’s take on the company. In May, UBS rerated challenger shares as a buy and upped its price target for the company as well. UBS also reckons the company will benefit from higher interest rates and is “on the cusp of a material rebound in life profitability”.

So given the Challenger share price has slid meaningfully since these bullish opinions were aired, it’s likely that UBS and TMS Captial are both still bullish on Challenger shares in June.

At the current Challenger share price, this ASX 200 financials share has a market capitalisation of $4.46 billion, with a dividend yield of 3.37%.

The post Is the Challenger share price cheap after sliding 13% in a month? appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#43B02A”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43B02A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• The Challenger share price is sliding 4% today. Is it a buy?

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Salesforce, Inc. The Motley Fool Australia has recommended Challenger Limited and Salesforce, Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/6t9WAdq

The Zip Co Ltd (ASX: ZIP) share price is soaring today, up 13.6% in early afternoon trading.

Zip shares closed yesterday trading for 44 cents and are currently swapping hands for 50 cents.

Certainly, that’s welcome news for Zip shareholders, who’ve watched the stock crash since hitting all-time highs in February last year.

ASX BNPL shares lifting off

It’s not just the Zip share price surging today. The wider ASX buy now, pay later (BNPL) sector is enjoying a strong showing.

The Sezzle Inc (ASX: SZL) share price is up 11.3% at the time of writing. And industry giant Block Inc (ASX: SQ2), which acquired Afterpay in January, is up 10.4%.

This as the All Ordinaries Index (ASX: XAO) is up a more modest 0.7%.

As the best performing of the BNPL shares today, the Zip share price could be getting a boost from its release earlier this week reporting that the company is “well placed to respond to and offset” rising interest rates.

The company also reported on its relatively strong financial position, with CEO Larry Diamond adding, “We have been clear that in response to current market conditions our strategic priorities are to focus on our core business, both products and regions, and accelerate the group’s path to profitability.”

Another factor that’s lifting the Zip share price and the wider ASX BNPL sector is the strong performance of the dual-listed Block on US markets yesterday (overnight Aussie time). Block closed up 10.9% on the NYSE.

The catalyst for that lift looks to be news breaking that Cathie Wood’s ARK Innovation fund acquired some 82,000 Block shares this week for almost $5 million.

Zip share price snapshot

Despite today’s big lift, the Zip share price remains down 88% in 2022. That compares to a year-to-date loss of 15% posted by the All Ordinaries.

Zip shares are also down 94% since this time last year and 43% over the past month.

The post The Zip share price is rocketing 14% today. What’s going on? appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#43B02A”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43B02A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• Why ASX 200 tech shares are outperforming the market on Friday
• ASX 200 midday update: Qantas’ market update, lithium shares rebound
• Block share price jumps 9% following Cathie Wood investment
• Why Cooper Energy, Lake Resources, Leo Lithium, and Zip shares are sinking
• Why ANZ, Block, Bubs, and PayGroup shares are pushing higher

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Block, Inc. and ZIPCOLTD FPO. The Motley Fool Australia has positions in and has recommended Block, Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/MJEYD5k

The LiveHire Ltd (ASX: LVH) share price is on the move during early afternoon trading on Friday.

This comes after the talent and direct sourcing solutions company announced it has teamed up with ManpowerGroup Talent Solutions.

At the time of writing, LiveHire shares are soaring 33.33% to 36 cents.

LiveHire seals milestone deal

Investors are pushing up the LiveHire share price on news the company’s strategic partnership will see it penetrate new markets.

In its release, LiveHire advised it has signed a strategic master services agreement with ManpowerGroup Talent Solutions on behalf of its TAPFIN division (TAPFIN).

The latter makes up part of the US$4.8 billion United States-listed ManpowerGroup Inc (NYSE: MAN).

TAPFIN is recognised as one of the four largest managed service providers (MSPs) in the world, per the release. The business manages more than US$20 billion in contingent spend through 103 countries.

Under the deal, LiveHire will serve as primary partner in offering direct sourcing solutions to TAPFIN’s North American clients. This will be on a non-exclusive basis.

LiveHire noted that there is further scope for the agreement to extend beyond North America. This includes access into other countries across Europe, the UK, and the Asia Pacific region.

The contract is based on LiveHire’s standard commercial terms. However, management is not able to put a value on the agreement because TAPFIN has not yet signed the first client to use the platform.

Nonetheless, LiveHire believes that due to the size of TAPFIN and its client base, the deal will be significant.

Commenting on the news driving the LiveHire share price today, CEO Christy Forest said:

We’re thrilled to have completed a competitive process conducted by TAPFIN, and to work with the TAPFIN team to bring our joint direct sourcing solution to TAPFIN’s clients.

About the LiveHire share price

Despite today’s astronomical gains, the LiveHire share price is trading relatively flat when looking over the last 12 months.

The company’s shares reached a 52-week low of 23.5 cents earlier this month before bouncing back to April 2022 levels.

LiveHire has a market capitalisation of roughly $80.28 million.

The post This small-cap ASX share is soaring 33% on strategic partnership news appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#43B02A”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43B02A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• Should you sell biotech stocks if there’s a recession?
• 2 fantastic international ETFs for ASX investors to buy
• Down 9% in a week, what’s going on with the Chalice Mining share price?
• Why are ASX 200 mining shares having such a dire week?
• Why is the Kogan share price jumping 12%?

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/Syae47k

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Commentators everywhere are professing that a recession is nigh, and there’s reason to believe they’re right. The market is down, inflation is up, and inventories are starting to bulge with unsold goods. If you’re feeling a mounting sense of doom, you’re definitely not alone. 

But none of the above are good reasons to sell your biotech stocks. In fact, there’s a compelling argument that recessions are exactly when you should be buying them. Let’s go through a few of the paradigms that explain why.

Here’s why selling might be ill-advised

The first reason to refrain from selling your biotech stocks during a recession is that the drug-development cycle is typically much longer than the duration of most recessions, and it can often take upwards of 12 years to move a candidate from early research through the entire clinical trials process. On average, recessions last 17.5 months, but the latest recession in early 2020 only lasted two months. Remember, most biotech companies can’t generate much in the way of revenue until they have a medicine that’s approved for sale. So if they don’t have any drugs on the market and a recession occurs, nothing changes about their sales. 

Nor does much of anything change about their chance of earning future sales as a result of successfully commercializing a medicine. Only around 20.9% of drug candidates manage to make it through the entire clinical trials process and reach the market, and failures along the way are almost always due to an unacceptable safety profile or weak efficacy. Economic factors can’t detract from or make up for a drug’s clinical performance, though they could negatively impact sales — but it’s not a given that sales will fall. 

Even for companies that already have products on the market, recessions aren’t a deal breaker because revenue can still grow when the economy is shrinking. Take Seagen‘s (NASDAQ: SGEN) performance during the Great Recession as an example. Its quarterly revenue grew by 62.9% from the middle of June in 2007 through the same time in 2009.

While its shares did still lose value during that period, their decline of around 6.5% was far less than the market’s collapse of more than 39.7%. And if you held your shares from right before the recession officially started until a year later, you’d be sitting on significant gains compared to the market’s performance — and that was true for more than just Seagen, as shown below:

^SPX data by YCharts.

That’s right: The industry-tracking SPDR S&P Biotech ETF beat the market both during and immediately after the recession. Especially for biotech investors who love to diversify within the industry, that’s a strong confirmation that selling your shares in the face of economic turmoil could be a big mistake.

It might even make sense to buy

For risk-tolerant investors, recessions are actually a great time to load up on shares of attractive biotechs when they’re cheaper than normal. The trick is to understand which companies have declining share prices because of events beyond their control and which are likely to struggle in a recessionary environment.  

Consider CRISPR Therapeutics (NASDAQ: CRSP) as an example; it has more than $2.2 billion in the bank but trailing 12-month operating expenses of only around $592 million. Its pipeline has a handful of mid-stage gene-editing therapies, and its share price bounced back promptly to smash the market’s return after the coronavirus crash and recession. Take a look:

^SPX data by YCharts.

As you can see, if you find biotechs that fit the bill, recessions can be an appealing time to invest. Biotechs with plenty of cash, minimal expenses, and pipelines packed with late-stage programs are positioned to withstand recessions better than others. Falling share prices make issuing new stock an unattractive way to raise funds, and having a lot of cash relative to research and development (R&D) expenses and operating expenses means that management can afford to wait for better conditions before doing an offering.

At the same time, companies with a lot of late-stage programs are closer to realizing revenue than others, which means they’ll also have an easier time getting debt financing if it’s necessary. If you already hold shares of the sturdier contenders, know that selling might well help you avoid some short-term losses — but there’s also a good chance it’ll preclude you from realizing long-term gains once the economy recovers.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

The post Should you sell biotech stocks if there’s a recession? appeared first on The Motley Fool Australia.

(function() { function setButtonColorDefaults(param, property, defaultValue) { if( !param || !param.includes(‘#’)) { var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0]; button.style[property] = defaultValue; } } setButtonColorDefaults(“#43B02A”, ‘background’, ‘#5FA85D’); setButtonColorDefaults(“#43B02A”, ‘border-color’, ‘#43A24A’); setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’); })()

More reading

• This small-cap ASX share is soaring 33% on strategic partnership news
• 2 fantastic international ETFs for ASX investors to buy
• Down 9% in a week, what’s going on with the Chalice Mining share price?
• Why are ASX 200 mining shares having such a dire week?
• Why is the Kogan share price jumping 12%?

Alex Carchidi has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CRISPR Therapeutics and Seagen Inc. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

from The Motley Fool Australia https://ift.tt/WsOUQv9

Exchange traded funds (ETFs) are very popular with investors and it isn’t hard to see why. Never has it been so easy for investors to gain access to groups of shares from all corners of the world.

But given how many ETFs there are to choose from, it can be hard to decide which ones to add to a portfolio. To narrow things down for readers, I have picked out two highly rated and popular ETFs to get better acquainted with today. They are as follows:

iShares S&P 500 ETF (ASX: IVV)

The first ASX ETF for investors to look at is the iShares S&P 500 ETF. This ETF aims to provide investors with the performance of Wall Street’s famous S&P 500 Index, before fees and expenses.

BlackRock, the operator of iShares, highlights that the ETF gives investors exposure to the top 500 U.S. stocks through a single investment. This allows Australian investors to use the fund to diversify internationally and seek long-term growth opportunities for a portfolio.

Among its largest holdings are Alphabet (Google), Amazon, Apple, JP Morgan, Johnson & Johnson, Meta (Facebook), Microsoft, Nvidia, and Tesla.

VanEck Vectors Morningstar Wide Moat ETF (ASX: MOAT)

Another ETF for investors to look at is the VanEck Vectors Morningstar Wide Moat ETF. This ETF gives investors access to a diversified portfolio of ~50 fairly priced US companies with sustainable competitive advantages or moats (hence the ETF’s name).

Companies with moats have historically generated strong returns for investors. As a result, it is for this reason that Warren Buffett looks for companies with this quality when picking investments. And given the strong returns the legendary investor has generated over the long term, it is hard to argue against this strategy.

If you buy this ETF you’ll be owning a slice of companies such as Alphabet, Amazon, Boeing, Microsoft, Salesforce, and Walt Disney.

The post 2 fantastic international ETFs for ASX investors to buy appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• Why I think better buying opportunities could still be ahead for ASX shares
• Here are 3 top ETFs for ASX investors to buy now
• Waiting to start investing in ASX shares? Today could be a brilliant time to do it
• 2 ASX growth shares I’d buy right away with $2,000
• 3 high quality ETFs for ASX investors to buy this month

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended VanEck Vectors Morningstar Wide Moat ETF and iShares Trust – iShares Core S&P 500 ETF. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/O9IGvoH

The Chalice Mining Ltd (ASX: CHN) share price has had a week to forget. But at least it’s not alone in its tumble. It’s been joined by many of its S&P/ASX 200 Index (ASX: XJO) resource peers.

At the time of writing, the Chalice Mining share price is picking up to trade at $3.75, 7.45% higher than its previous close. Though, that’s still 8.53% lower than it was at the end of last week.

For context, the ASX 200 is also up 0.28% today while the All Ordinaries Index (ASX: XAO) has gained 0.5%.

Let’s take a closer look at what might have gone wrong for the ASX 200 mineral explorer and developer’s stock this week.

What’s weighing on the Chalice Mining share price?

The Chalice Mining share price is regaining some of its previous tumble today. It’s suffered lately amid a sell-off among resource shares and sliding commodity prices.

Many of the company’s projects house on copper, nickel, gold, and platinum group elements.

Unfortunately, the prices of both copper and nickel have slipped more than 5% over the last week on the London Metal Exchange. The fall has left the price of nickel at its lowest point since February while copper is trading at 16-month lows.

Meanwhile, gold futures have slipped 1% over the course of this week, according to CommSec.

The commodities’ downturn might have weighed on the Chalice Mining share price this week despite Goldman Sachs increasing its voting power in the company by around 1% to reach 9.2% on Monday after selling a similar amount earlier this month.

It’s likely also dragging on the S&P/ASX 200 Resources Index (ASX: XJR). The sector has fallen 5.3% since last Friday’s close.

The last time the market heard news from Chalice Mining was nearly a month ago. Then, the company announced it had successfully completed a $100 million institutional placement.

The placement saw the company offering news shares for $6 apiece. That marked a 10% discount to the Chalice Mining share price.

Since then, the stock has plunged 39%. It has also fallen 58% since the start of 2022 and 47% since this time last year.

The post Down 9% in a week, what’s going on with the Chalice Mining share price? appeared first on The Motley Fool Australia.

(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}

setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()

More reading

• Chalice Mining share price spikes 6%, reversing series of losses
• These were the worst performing ASX 200 shares last week
• Here’s why the Chalice Mining share price sank almost 7% today
• Why BHP, BrainChip, Chalice Mining, and Fisher & Paykel shares are dropping

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

from The Motley Fool Australia https://ift.tt/qRn8Jkr